Document Detail


Serum levels of soluble CD40 ligand at flare and at remission in patients with systemic lupus erythematosus.
MedLine Citation:
PMID:  19332622     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To perform a prospective evaluation of soluble CD40 ligand (sCD40L) levels according to the activity of systemic lupus erythematosus (SLE). METHODS: Two serum samples were taken from 53 patients with SLE: at flare and at remission. Clinical and biological measures (sCD40L levels were measured by a commercial ELISA) were evaluated in both situations. RESULTS: Patients with SLE had significantly lower median levels of sCD40L during flare than during remission [3365 (6157) vs 7125 (4122) pg/ml; p < 0.001]. The multivariate analysis to explain those patients with lower values of sCD40L during flare than during remission included 3 variables: 2 related to flare (prednisone dose received <or= 15 mg/day and platelet counts > 192,000 x 10(6)/l) and one related to lower changes in SLE Disease Activity Index (SLEDAI) score. We regrouped patients with the 2 characteristics related to flare as Group 4, and the others were Group 123. All patients with low SLEDAI scores at flare had statistically significant lower sCD40L levels during flare than during remission. When flare SLEDAI scores were higher than the 50th percentile, patients of Group 123 showed the same behavior and even more diminished levels of sCD40L during flare than patients of Group 123 with low SLEDAI scores (p = 0.023); and patients of Group 4 showed no differences in the values of sCD40L between flare and remission (p = 0.241). CONCLUSION: sCD40L plays a biologically active role, with decreased levels at flare at low SLEDAI scores. At high SLEDAI scores there are mechanisms that involve platelets and that are inhibited by high doses of prednisone that lead to increased serum values of sCD40L at flare.
Authors:
Maria Urquizu-Padilla; Eva Balada; Fina Cortés; Eduardo Hermosilla Pérez; Miquel Vilardell-Tarrés; Josep Ordi-Ros
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-03-30
Journal Detail:
Title:  The Journal of rheumatology     Volume:  36     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-05-13     Completed Date:  2009-06-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  953-60     Citation Subset:  IM    
Affiliation:
Systemic Autoimmune Diseases Research Laboratory, Vall d'Hebron Research Institute, Hospital Vall d'Hebron, Barcelona, Spain. mariaurquizu@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
CD40 Ligand / blood*
Child
Disability Evaluation
Female
Health Status
Humans
Lupus Erythematosus, Systemic / blood*,  physiopathology
Male
Middle Aged
Prospective Studies
Recurrence
Remission Induction
Severity of Illness Index
Young Adult
Chemical
Reg. No./Substance:
147205-72-9/CD40 Ligand

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  State-dependent modulation of CFTR gating by pyrophosphate.
Next Document:  Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.